In recent years, constant progress in science and technology has resulted in innovative molecules addressing core mechanisms of myocardial disease affecting millions worldwide [1]. A targeted molecular approach, well established in oncology over the last two decades, is likely to revolutionize a field, such as cardiovascular therapeutics, long dominated by agents modulating neuroendocrine systems and ion channels rather than myocardial function. The sarcomere is the fundamental unit of striated muscle contraction, containing myosin, a protein that converts chemical energy into mechanical force through its interaction with actin.
